Advancements in iTTP Treatment: The Role of Caplicizumab

Immune thrombotic thrombocytopenic purpura (iTTP) is a rare coagulopathic disorder characterized by immune-mediated thrombocytopenia and microangiopathic hemolytic anemia, that can cause life-threatening thrombosis. Coauthor Allyson M. Pishko, MD, MSCE, of the University of Pennsylvania joins JAMA Associate Editor David Simel, MD, MHS, to discuss the recent review of iTTP published in JAMA. Related Content:

• Immune Thrombotic Thrombocytopenic Purpura